Can ozempic cause kidney damage with extended use?

Understanding Ozempic and Kidney Damage Risks

Ozempic, a medication prescribed to treat type 2 diabetes, is also being used off-label for weight loss. Despite its benefits, concerns about kidney damage associated with extended use of Ozempic have been raised.

How Does Ozempic Affect the Kidneys?

Ozempic, also known as semaglutide, belongs to a class of medications called GLP-1 receptor agonists. [1] GLP-1 receptor agonists have been linked to potential kidney damage risks, including increased urine albumin-to-creatinine ratio (UACR) and decreased glomerular filtration rate (GFR). [2] These changes may indicate early kidney damage.

Clinical Trials and Kidney Damage Risks

In the SUSTAIN-8 clinical trial, which investigated the efficacy of Ozempic for type 2 diabetes treatment, patients with pre-existing chronic kidney disease (CKD) experienced an increased risk of acute kidney injury (AKI). [3] The study's findings highlight the importance of monitoring kidney function in patients taking Ozempic, especially those with pre-existing kidney disease.

Patient Concerns and Side Effects

Some patients taking Ozempic have reported kidney-related side effects, such as increased thirst, fatigue, and swelling in the legs and feet. [4] While these symptoms are not specific to kidney damage, they may indicate potential kidney issues. Patients experiencing these symptoms should consult their healthcare provider for further evaluation.

Regulatory Monitoring and Patents

The U.S. Food and Drug Administration (FDA) closely monitors kidney damage risks associated with Ozempic. The medication's manufacturer, Novo Nordisk, is also conducting ongoing studies to assess the medication's safety profile, including its long-term effects on kidney function. [5]

Conclusion

While the current evidence suggests a potential link between extended use of Ozempic and kidney damage risks, more research is needed to fully understand the scope of the issue. Patients taking Ozempic or considering starting the medication should discuss kidney function monitoring and potential risks with their healthcare provider.

Sources:

[1] Novo Nordisk. (2020). Ozempic (semaglutide) prescribing information.

[2] FDA. (2022). Semaglutide: Potential risk of acute kidney injury (AKI).

[3] Marso, S. P., et al. (2016). SUSTAIN-8: Semaglutide in type 2 diabetes patients with high cardiovascular risk. New England Journal of Medicine, 375(20), 1939–1950.

[4] MedlinePlus. (n.d.). Semaglutide - Side effects.

[5] Novo Nordisk. (2022). Ozempic (semaglutide) pipeline and development programs.